ArticleJournal of translational medicine2026
YY1-induced upregulation of DLGAP5 promotes tumor progression in lung adenocarcinoma via Wnt/β-catenin/EMT pathway.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDLGAP5 is frequently upregulated in human cancers and is associated with tumor progression. However, its biological role, regulatory mechanism, and downstream signaling in lung adenocarcinoma (LUAD) remain unclear.
methodsPublic databases were used to analyze DLGAP5 expression, diagnostic value, and prognostic significance across cancers, especially in LUAD. Functional assays in LUAD cells and xenograft models were performed to evaluate the effects of DLGAP5 on proliferation, migration, invasion, and tumor growth. Mechanistic studies were conducted to examine cell cycle- and EMT-related proteins, as well as the transcriptional regulation of DLGAP5 by YY1.
resultsDLGAP5 was significantly upregulated in multiple cancers and showed strong diagnostic value. High DLGAP5 expression predicted poor overall survival and disease-specific survival, and was an independent prognostic factor in LUAD. DLGAP5 knockdown inhibited LUAD cell proliferation, migration, invasion, and tumor growth. Mechanistically, DLGAP5 silencing reduced CDK4 and CDK6 expression and suppressed the Wnt/β-catenin/EMT pathway, as shown by decreased N-cadherin, Slug, Snail, Twist1, and β-catenin, with increased E-cadherin. In addition, YY1 directly bound to the DLGAP5 promoter and positively regulated its expression. YY1 knockdown reduced DLGAP5 expression and impaired LUAD progression.
conclusionsDLGAP5 promotes LUAD progression by enhancing cell proliferation, metastasis, and EMT, while YY1 acts as its upstream transcriptional activator. The YY1/DLGAP5 axis may serve as a potential prognostic biomarker and therapeutic target in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.